Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DRIO
DRIO logo

DRIO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy DarioHealth Corp (DRIO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.930
1 Day change
-2.81%
52 Week Range
17.740
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

DarioHealth Corp (DRIO) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently in a bearish trend with no significant positive catalysts or trading signals to support an immediate investment. Additionally, hedge funds are selling, and the technical indicators suggest further downside potential. It's best to wait for more favorable conditions or clear signs of reversal before considering a position.

Technical Analysis

The stock is in a bearish trend with MACD negatively expanding (-0.0536), RSI indicating oversold conditions (19.922), and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support levels are at 6.973 and 6.784, while resistance levels are at 7.584 and 7.773.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
4

Positive Catalysts

  • RSI indicates oversold conditions, which may suggest a potential rebound in the short term.

Neutral/Negative Catalysts

  • Hedge funds are selling heavily (109.67% increase in selling over the last quarter). No recent news or significant insider activity. No recent congress trading data. Bearish technical indicators and no AI Stock Picker or SwingMax signals.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target updates available.

Wall Street analysts forecast DRIO stock price to rise
2 Analyst Rating
Wall Street analysts forecast DRIO stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 7.130
sliders
Low
11
Averages
13.5
High
16
Current: 7.130
sliders
Low
11
Averages
13.5
High
16
Stifel
Buy
downgrade
$16 -> $10
AI Analysis
2026-03-20
Reason
Stifel
Price Target
$16 -> $10
AI Analysis
2026-03-20
downgrade
Buy
Reason
Stifel lowered the firm's price target on DarioHealth to $10 from $16 and keeps a Buy rating on the shares. The firm continues to model 2025 and 2026 revenue and EBITDA estimates below consensus as visibility on timing of the signing and ramp of contracts remains limited, adding that the stock is "unlikely to regain momentum until there is better visibility on revenue growth acceleration and achieving profitability."
Stifel
David Grossman
Buy
maintain
$16
2025-11-14
Reason
Stifel
David Grossman
Price Target
$16
2025-11-14
maintain
Buy
Reason
Stifel analyst David Grossman adjusted the firm's price target on DarioHealth to $16 from $1.25 and keeps a Buy rating on the shares. While "encouraged" by management's ability to lower expenses and continue to sign meaningful new customer relationships, the firm views the stock as unlikely to regain momentum until there are visible signs of accelerating revenue growth and a path to profitability. Following the 20-1 reverse stock split, the firm notes that its prior price target of $1.25 would have equated to $25.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for DRIO
Unlock Now

People Also Watch